CD8A and ovarian carcinoma: Specifically, high frequency of intraepithelial CD8+ T cells expressing the αE integrin subunit CD103, which may serve as a novel marker for enriching the most beneficial subsets of TILs for immunotherapy, correlates with enhanced survival in ovarian cancer, suggesting that CD8+ T lymphocytes directly contribute to the anticancer effects (Komdeur et al., 2016; Sato et al., 2005b; Webb et al., 2014).